Special populations : אוכלוסיות מיוחדות

Geriatric Use
Clinical studies of clotrimazole did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

DRUG ABUSE AND DEPENDENCE
No data available.

Important information about some of the ingredients of the medicine
Patients with rare glucose-galactose malabsorption should not take this medicine. Agisten lozenges contains 888 mg dextrose per lozenge.

4.5 Interaction with other medicinal products and other forms of interaction
Not known

4.6 Fertility, pregnancy and lactation
Usage in Pregnancy: Pregnancy Category C

Clotrimazole has been shown to be embryotoxic in rats and mice when given in doses 100 times the adult human dose (in mg/kg), possibly secondary to maternal toxicity. The drug was not teratogenic in mice, rabbits, and rats when given in doses up to 200, 180 and 100 times the human dose.

Clotrimazole given orally to mice from nine weeks before mating through weaning at a dose 120 times the human dose was associated with impairment of mating, decreased number of viable young, and decreased survival to weaning. No effects were observed at 60 times the human dose.
When the drug was given to rats during a similar time period at 50 times the human dose, there was a slight decrease in the number of pups per litter and decreased pup viability.

There are no adequate and well controlled studies in pregnant women. Agisten Lozenges should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.